VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites

Autor: Katrin J. Czogalla, Kerstin Liphardt, Klara Höning, Veit Hornung, Arijit Biswas, Matthias Watzka, Johannes Oldenburg

Publikováno v: Blood Advances, Vol 2, Iss 6, Pp 691-702 (2018)

Abstract: Vitamin K reduction is catalyzed by 2 enzymes in vitro: the vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) and its isozyme VKORC1-like1 (VKORC1L1). In vivo, VKORC1 reduces vitamin K to sustain γ-carboxylation of vitamin K-depen

Externí odkaz: https://doaj.org/article/f4c0d6d5c29042b79cd901c0209c7844

Selective Modulation of the Protease Activated Protein C Using Exosite Inhibiting Aptamers

Autor: Günter Mayer, Jens Müller, Nasim Shahidi Hamedani, Heiko Rühl, Bernd Pötzsch, Fabian Tolle, Johannes Oldenburg, Behnaz Pezeshkpoor, Kerstin Liphardt

Publikováno v: Nucleic Acid Therapeutics. 30:276-288

Activated protein C (APC) is a serine protease with anticoagulant and cytoprotective activities. Nonanticoagulant APC mutants show beneficial effects as cytoprotective agents. To study, if such biased APC signaling can be achieved by APC-binding liga

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b19acc50f15588aad13f68bb69aa4e3e
https://doi.org/10.1089/nat.2020.0844

Warfarin and vitamin K compete for binding to Phe55 in human VKOR

Autor: Katrin J. Czogalla, Veit Hornung, Kerstin Liphardt, Arijit Biswas, Matthias Watzka, Klara Höning, Johannes Oldenburg

Publikováno v: Nature Structural & Molecular Biology. 24:77-85

Vitamin K epoxide reductase (VKOR) catalyzes the reduction of vitamin K quinone and vitamin K 2,3-epoxide, a process essential to sustain γ-carboxylation of vitamin K-dependent proteins. VKOR is also a therapeutic target of warfarin, a treatment for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7623221f4c051717708fafa9d0720f9
https://doi.org/10.1038/nsmb.3338

Variants in FIX propeptide associated with vitamin K antagonist hypersensitivity: functional analysis and additional data confirming the common founder mutations

Autor: Michael Caspers, Marco Kellner, Silvia Ulrich, Katrin J. Czogalla, Kerstin Liphardt, Ann-Cristin Berkemeier, Anna Pavlova, S Ghosh, Johannes Oldenburg, Behnaz Pezeshkpoor

Publikováno v: Annals of hematology. 97(6)

One of the most common and unwanted side effects during oral anticoagulant therapy (OAT) is bleeding complications. In rare cases, vitamin K antagonist (VKA)-related bleeding events are associated with mutations affecting the F9 propeptide at amino a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be20c882a83a83841d6255053461a34
https://pubmed.ncbi.nlm.nih.gov/29450643

Quality of life in a large multinational haemophilia B cohort (The B‐Natural study) – Unmet needs remain.

Autor: Berntorp, Erik¹ (AUTHOR) erik.berntorp@med.lu.se, LeBeau, Petra² (AUTHOR), Ragni, Margaret V.³ (AUTHOR), Borhany, Munira⁴ (AUTHOR), Abajas, Yasmina L.⁵ (AUTHOR), Tarantino, Michael D.⁶ (AUTHOR), Holstein, Katharina⁷ (AUTHOR), Croteau, Stacy E.⁸ (AUTHOR), Liesner, Raina⁹ (AUTHOR), Tarango, Cristina¹⁰ (AUTHOR), Carvalho, Manuela¹¹ (AUTHOR), McGuinn, Catherine¹² (AUTHOR), Funding, Eva¹³ (AUTHOR), Kempton, Christine L.¹⁴ (AUTHOR), Bidlingmaier, Christoph¹⁵ (AUTHOR), Cohen, Alice¹⁶ (AUTHOR), Oldenburg, Johannes¹⁷ (AUTHOR), Kearney, Susan¹⁸ (AUTHOR), Knoll, Christine¹⁹ (AUTHOR), Kuriakose, Philip²⁰ (AUTHOR)

Publikováno v: Haemophilia. May2022, Vol. 28 Issue 3, p453-461. 9p. 1 Chart, 2 Graphs.